VpH

VpH is a biotechnology company focused on developing novel cancer therapeutics that target the acidic microenvironment of solid tumors. The company's primary technology centers on the inhibition of V-ATPase (vacuolar-type H+-ATPase), a proton pump that is often overexpressed in cancer cells to maintain intracellular pH and acidify the extracellular space. By disrupting this pH regulation mechanism, VpH aims to induce apoptosis in cancer cells and enhance the efficacy of existing chemotherapies. The company is currently in the pre-clinical stage, advancing a pipeline of small molecule inhibitors designed to selectively target tumor-associated V-ATPase isoforms.